RYBREVANT conc perf 350 mg/7ml
7680683800017
CH-68380
L01FX18
07.16.1.
Reimbursement limitations:
RYBREVAN.01a
2L CBNPC (monothérapie)
RYBREVANT est remboursé en monothérapie pour le traitement des patients atteints d'un …
1 / 3
google
Details
- Product number
- 6838001
- CPT
- -
- Packaging group
- 1
- Unit
- Durchstechflasche(n)
- Composition
- amivantamabum 350 mg, histidinum, histidini hydrochloridum monohydricum, saccharum, polysorbatum 80, dl-methioninum, dinatrii edetas, aqua ad iniectabile q.s. ad solutionem pro 7.0 ml corresp. natrium 17 µg.
Articles (1)
Rybrevant 350 mg/7 ml, Konzentrat zur Herstellung einer Infusionslösung
Konzentrat
1
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
(N/A)
|
350.0 MG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
17.0 UG | Substance | HBESI |
Reimbursement information
Public price
CHF 1299.00
Specialties list
Yes
Generic
No
Reimbursement limitation
SL addition date:
01/09/2022
Authorization holder
Janssen-Cilag AG
6300 Zug
Authorization information
- Swissmedic authorization number
- 68380
- Drug name
- Rybrevant, Konzentrat zur Herstellung einer Infusionslösung
- Galenic form
- KOINF
- ATC Code
- L01FX18
- Authorization status
- Z
- Dispensation category
- A
- First authorization
- 20/01/2022
- Authorization expiration date
- 01/05/2029
- IT number
- 07.16.1.
- Domain
- Human medicine
Packaging details
- Description (FR)
- RYBREVANT conc perf 350 mg/7ml
- Description (DE)
- RYBREVANT Inf Konz 350 mg/7ml
- Market launch
- 20/01/2022
- Narcotic (BTM)
- No